MitoQ to Improve Vascular Funciton in Preeclampsia
Recruiting · NCT07229261 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.
Who can take part
Inclusion criteria
- Inpatient Cohort
- pregnant patients with a clinical diagnosis of preeclampsia with severe features
- gestational age between 23+0 and 32+0 weeks' gestation
- singleton pregnancy
- age 18-50 years old
- No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features
- Able to consent and follow a 2-step commend
- English speaking
- Outpatient Cohort
- Pregnant patients with a clinical diagnosis of preeclampsia without severe features
- gestational age between 23+0 and 34+0 weeks' gestation
- singleton pregnancy
- age 18-50 years old
- No indication for immediate delivery
- Planned outpatient management of preeclampsia
- Able to consent and follow a 2-step commend
- English speaking
Exclusion criteria
- • Unable to stand from chair without physical assistance from another person (able to use assistive device).
- History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg).
- Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization)
- History of head trauma or concussion within the past 6 months
- Comorbid neurological disorder
- Peripheral vascular disease
- Diagnosed myocardial infarction or arrhythmia in the previous year
- Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg
- Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator
Where it is running
1 location listed across 1 US state.
- Froedtert & the Medical College of Wisconsin - Milwaukee, Wisconsin, United States